14 February 2022. China’s top drug regulator has given conditional approval for Pfizer’s COVID-19 treatment Paxlovid, making it the first oral pill for the disease approved in the country. The drug can be used to treat adults who have mild to moderate symptoms and a high risk of progressing to more severe disease.https://www.chinadaily.com.cn/a/202202/14/WS62098fc5a310cdd39bc864ed.html